Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05219799 · ClinicalTrials.gov registry record · Early Phase 1

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

A Early Phase 1 study of Healthy and Obesity, sponsored by University of Missouri-Columbia.

Recruiting
Registry status
Early Phase 1
Development phase
72
Enrollment target
1
Study location

NCT05219799 is a Early Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 72 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05219799, a Early Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by University of Missouri-Columbia.

RECRUITING
Registry status
Early Phase 1
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.

Interventions

  • DRUG Norepinephrine
  • DRUG Isoproterenol
  • DRUG Propranolol Hydrochloride
  • DRUG Phentolamine Mesylate

Study Locations (1)

Missouri

  • University of Missouri - Columbia

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2023-03-14
Est. Completion 2026-06-30
Phase Early Phase 1

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT05219799

The ClinicalTrials.gov registry entry for NCT05219799 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Norepinephrine is the first listed.

NCT05219799 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05219799 about?

NCT05219799 is a clinical study titled "Sex Disparities in Hypoxic Vasodilation and Impact of Obesity". The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.

What is the current status of trial NCT05219799?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2023-03-14. Estimated completion is 2026-06-30.

What conditions does trial NCT05219799 study?

This clinical trial studies the following conditions: Healthy, Obesity, Vasodilation.

What interventions are being tested in trial NCT05219799?

The interventions under investigation include: Norepinephrine (DRUG), Isoproterenol (DRUG), Propranolol Hydrochloride (DRUG), Phentolamine Mesylate (DRUG).

Who is sponsoring clinical trial NCT05219799?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05219799 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.